Hydrogen rescues vascular endothelial cells in obstructive sleep apnea-hypopnea syndrome by modulating nitric oxide
Chen Q, Jiang D, He J, Sun M. · Journal of thoracic disease. 2025;17(11):9598-9609.
What kind of evidence is this?
Preclinical
Controlled animal and cell study
Cardiovascular and circulatory health
Other forms
Not reported in this record.
Not reported in this record.
Methods at a glance
cells, rats, rat, cell used to study cardiovascular and circulatory health.
Preclinical study; group or assay counts reported in the full text include n=6, n=3.
5 min
Full text reports H₂ dissolved in cell-culture medium. Detected intervention quantities or schedules: 8%, 5 min, 21%, 4 weeks, 2%, 1%, 10 min, 24 hours, 0.6 mM, 99.99%.
H₂ dissolved in cell-culture medium — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 8%, 5 min, 21%, 4 weeks, 2%, 1%, 10 min, 24 hours, 0.6 mM, 99.99%. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “Treatment with H_2-rich medium (0.6 mM) during IH exposure significantly reduced ROS production by 60% (P<0.001 vs.” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. Funding or grant information is reported in the full article. The article declares no conflicts of interest.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 41376930 · DOI: 10.21037/jtd-2025-1345
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10